On June 2, Intellia Therapeutics' (NTLA -0.96%) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. This is a good omen Such patients might still technically have the disorder, as it is currently impossible for 100% of the copies of their genes, which are distributed across the my ...